Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Djoke Hendriks"'
Autor:
Anna V. Silven, Petra G. van Peet, Sarah N. Boers, Monique Tabak, Aviva de Groot, Djoke Hendriks, Hendrikus J. A. van Os, Tobias N. Bonten, Douwe E. Atsma, Tycho J. de Graaf, Mirjam P. Sombroek, Niels H. Chavannes, María Villalobos-Quesada
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Implementation of digital health (eHealth) generally involves adapting pre-established and carefully considered processes or routines, and still raises multiple ethical and legal dilemmas. This study aimed to identify challenges r
Externí odkaz:
https://doaj.org/article/8de17b795bcc4842ad86fe8cfa791d66
Autor:
Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer, Wijnand Helfrich
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced
Externí odkaz:
https://doaj.org/article/e22cb3f785134639905fdb9be9107749
Autor:
Yunwei Wei, Valerie R. Wiersma, Marloes J. M. Gooden, Wijnand Helfrich, Djoke Hendriks, Hans W. Nijman, Douwe F. Samplonius, Jin Zhou, Maartje C.A. Wouters, Marco de Bruyn, Ce Shi, Edwin Bremer
Publikováno v:
mAbs, 7(2), 321-330
The therapeutic effect of anti-cancer monoclonal antibodies stems from their capacity to opsonize targeted cancer cells with subsequent phagocytic removal, induction of antibody-dependent cell-mediated cytotoxicity (ADCC) or induction of complement-m
Since their discovery, antibodies have been viewed as ideal candidates or "magic bullets" for use in targeted therapy in the fields of cancer, autoimmunity, and chronic inflammatory disorders. A wave of antibody-dedicated research followed, which res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39d295b05c3ba0ca15179bbb38b15990
https://doi.org/10.1016/bs.ircmb.2016.10.002
https://doi.org/10.1016/bs.ircmb.2016.10.002
Publikováno v:
ACS Synthetic Biology, 2(7), 397-404. AMER CHEMICAL SOC
Lanthipeptides are peptides that contain several post-translationally modified amino acid residues and commonly show considerable antimicrobial activity. After translation, the amino acid residues of these peptides are modified by a distinct set of m
Autor:
Gessa Sugiyarto, Surinder S. Sahota, Francesco Forconi, Nicola J. Weston-Bell, Hanneke C. Kluin-Nelemans, Nicolaas A. Bos, Djoke Hendriks
Publikováno v:
Leukemia, 27(1), 241-245. Nature Publishing Group
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins
Autor:
Oscar P. Kuipers, Baptiste Baudu, Annechien Plat, Tomas G. Kloosterman, Jingjing Deng, Auke J. van Heel, Gert N. Moll, Manuel Montalbán-López, Djoke Hendriks
Publikováno v:
ACS synthetic biology. 5(10)
To find the right conditions to isolate natively expressed antimicrobial peptides from a wide range of different microorganisms can be a challenge. Here, we exploited a heterologous expression system to produce and characterize several novel lantibio
Autor:
Robert J. van Ginkel, Djoke Hendriks, Edwin Bremer, Douwe F. Samplonius, Yuan He, Wijnand Helfrich
Publikováno v:
Journal of Investigative Dermatology, 136(2), 541-544. ELSEVIER SCIENCE INC
lymphopoietin expression in parallel with a reduction in serine protease activity and elevation in b-glucocerebrosidase activity (Figures 1 and 2, and Supplementary Figures S1 and S2), suggesting not only that coapplication of PAR2 antagonist and LBA
Autor:
Valerie R. Wiersma, Wijnand Helfrich, R.J. van Ginkel, Yuan He, Djoke Hendriks, Iris Koopmans, Edwin Bremer, Douwe F. Samplonius
Publikováno v:
OncoImmunology, 5(8):1202390. Taylor & Francis Group
Oncoimmunology
Oncoimmunology
Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of functionally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in various advanced cancers, particularly in melanoma. However, only a subset of